Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI3003 |
| Synonyms | |
| Therapy Description |
IBI3003 is a T-cell engager targeting GPRC5D and TNFRSF17 (BCMA) on tumor cells and CD3 on T-cells, which potentially induces a cytotoxic T-cell response against tumor cells expressing GPRC5D and TNFRSF17 (BCMA) (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI3003 | IBI-3003|IBI 3003 | CD3 Antibody 119 TNFRSF17 Antibody 22 | IBI3003 is a T-cell engager targeting GPRC5D and TNFRSF17 (BCMA) on tumor cells and CD3 on T-cells, which potentially induces a cytotoxic T-cell response against tumor cells expressing GPRC5D and TNFRSF17 (BCMA) (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06083207 | Phase Ib/II | IBI3003 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | AUS | 1 |